Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02944461 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris

A Phase 4 study of Acne, sponsored by Derm Research, P.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
3
Study locations

NCT02944461 is a Phase 4 study of Acne that has completed, run by Derm Research, P. The registered enrollment target is 20 participants, below the 142-participant average among 26 other Acne trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02944461, a Phase 4 study of Acne, has completed, sponsored by Derm Research, P.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
3
Study locations

Study Summary

To determine if Dapsone (Aczone) 7.5% gel is a safe and effective treatment for acne on the trunk

Conditions Studied

Interventions

  • DRUG Dapsone 7.5 % gel

Study Locations (3)

California

  • Dermatology and Laser Surgery - Sacramento

Kentucky

  • DermResearch, PLLC - Louisville

Nevada

  • James Q. DelRosso DO, LLC - Las Vegas

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2016-10
Est. Completion 2017-09-11
Phase Phase 4

Sponsor

Derm Research, P

3 total trials

What the Registry Record Tells You About NCT02944461

The ClinicalTrials.gov registry entry for NCT02944461 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 26 other Acne trials with a reported enrollment target (86% lower). The listed sponsor is Derm Research, P, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 1 intervention - of which Dapsone 7.5 % gel is the first listed.

NCT02944461 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Kentucky, Nevada.

Frequently Asked Questions

What is clinical trial NCT02944461 about?

NCT02944461 is a clinical study titled "Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris". To determine if Dapsone (Aczone) 7.5% gel is a safe and effective treatment for acne on the trunk

What is the current status of trial NCT02944461?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2016-10. Estimated completion is 2017-09-11.

What conditions does trial NCT02944461 study?

This clinical trial studies the following conditions: Acne.

What interventions are being tested in trial NCT02944461?

The interventions under investigation include: Dapsone 7.5 % gel (DRUG).

Who is sponsoring clinical trial NCT02944461?

This trial is sponsored by Derm Research, P, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02944461 being conducted?

This trial has 3 study locations across California, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.